摘要
胃癌是全球第5大常见恶性肿瘤,腹膜转移是其主要死亡原因。高患病率与早期诊断的缺乏导致了多数病人确诊时已进入进展期,进展期胃癌手术后极易发生腹膜转移,目前尚无特别有效的方法预防胃癌手术后腹膜种植转移。大量临床实践证明,腹腔热灌注化疗(hyperthermic intraperitoneal chemotherapy,HIPEC)是一种高效的治疗肿瘤腹膜转移的方法,把HIPEC应用到胃癌围手术期,可能成为一种高效的预防胃癌术后腹膜种植转移的新方法,被越来越多的临床机构所研究及应用。该文对HIPEC在预防胃癌根治术后腹膜转移的有效性、适应证、操作模式、药物选择、安全性等方面的研究、进展及HIPEC的应用前景进行了系统的综述,以期为HIPEC的应用及技术突破提供参考。
Gastric cancer(GC)ranks as the fifth most prevalent malignancy globally,and peritoneal metastasis serves as the primary cause of mortality.The high incidence rate and lack of early diagnostic methods challenge the early diagnosis of GC.Most patients have been diagnosed as advanced stages.Peritoneal metastasis frequently occurs after surgery in advanced GC cases,and no particularly effective strategies currently exist to prevent postoperative peritoneal implantation metastasis.A substantial body of clinical evidence supports the efficacy of hyperthermic intraperitoneal chemotherapy(HIPEC)in treating peritoneal metastasis,and its application during the perioperative period of gastric cancer may offer a novel and effective approach for preventing postoperative peritoneal implantation metastasis.HIPEC is gaining increasing attention from clinical institutions for research and application.This review systematically examined the research progress,efficacy,indications,procedural modalities,drug selection,safety,and future perspectives of HIPEC in preventing peritoneal metastasis after GC radical surgery,aiming to provide valuable insights for its application and technological advancement.
作者
谭华志
沈晓军
韩玮
史立洲
刘沐阳
王睿杰
Tan Huazhi;Shen Xiaojun;Han Wei;Shi Lizhou;Liu Muyang;Wang Ruijie(Department of Gastrointestinal Surgery,the First People's Hospital of Kunshan Affiliated with Jiangsu University,Jiangsu Kunshan 215300)
出处
《腹部外科》
2025年第4期321-325,共5页
Journal of Abdominal Surgery
基金
昆山市第一人民医院医疗卫生科技创新专项重点项目(KSKFOYLWS2023002)。
关键词
腹腔热灌注化疗
胃癌
复发
安全性
腹膜转移
Hyperthermic intraperitoneal chemotherapy
Gastric cancer
Recurrence
Safety
Peritoneal metastasis
